Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2017	Dec. 31, 2016
Current Assets:
Cash and cash equivalents	$ 169,019	$ 154,901
Marketable securities	285,085	236,949
Accounts receivable, net of reserves of $4,873 in 2017 and $4,523 in 2016	228,159	204,494
Inventories	176,749	158,034
Other current assets	83,710	91,206
Total current assets	942,722	845,584
Long-Term Assets:
Property and equipment, net	367,513	357,422
Goodwill	199,521	178,228
Intangible assets, net	45,251	46,155
Other long-term assets	114,327	103,315
Total long-term assets	726,612	685,120
TOTAL ASSETS	1,669,334	1,530,704
Current Liabilities:
Accounts payable	60,583	60,057
Accrued liabilities	220,507	236,131
Line of credit	686,250	611,000
Current portion of deferred revenue	29,203	27,380
Total current liabilities	996,543	934,568
Long-Term Liabilities:
Deferred income tax liabilities	33,205	39,287
Long-term debt	604,149	593,110
Long-term deferred revenue, net of current portion	34,245	33,015
Other long-term liabilities	49,583	38,937
Total long-term liabilities	721,182	704,349
Total liabilities	1,717,725	1,638,917
Commitments and Contingencies (Note 14)
Stockholders’ Deficit:
Common stock, $0.10 par value: Authorized: 120,000 shares; Issued: 104,120 shares in 2017 and 103,341 shares in 2016	10,412	10,334
Additional paid-in capital	1,060,689	1,011,895
Deferred stock units: Outstanding: 229 units in 2017 and 231 units in 2016	5,944	5,514
Retained earnings	765,288	540,401
Accumulated other comprehensive loss	(34,648)	(43,053)
Treasury stock, at cost: 16,819 shares in 2017 and 15,367 shares in 2016	(1,856,307)	(1,633,443)
Total IDEXX Laboratories, Inc. stockholders’ deficit	(48,622)	(108,352)
Noncontrolling interest	231	139
Total stockholders’ deficit	(48,391)	(108,213)
TOTAL LIABILITIES AND STOCKHOLDERS’ DEFICIT	$ 1,669,334	$ 1,530,704